Phase II study of irinotecan+5FU/FA for patients with previously treated advanced gastric cancer.

被引：0
|
作者：
Peeters, M
Van Laethem, JL
Baert, F
Canon, JL
De Grève, J
Kalantari, H
Dhont, P
Van Cutsem, E
机构：
[1] State Univ Ghent Hosp, B-9000 Ghent, Belgium
[2] Erasme Univ Hosp, B-1070 Brussels, Belgium
[3] H Hart Hosp, Roeselare, Belgium
[4] Clin Notre Dame, Charleroi, Belgium
[5] Univ Brussels, Acad Ziekenhuis, Ghent, Belgium
[6] Ctr Hosp Peltzer La Tourelle, Verviers, Belgium
[7] Aventis Pharma, Brussels, Belgium
[8] Katholieke Univ Leuven, Hosp Gasthuisberg, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4076
引用
收藏
页码：332S / 332S
页数：1
相关论文
共 50 条
  • [21] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Takahide, Sasaki
    Yasuyuki, Kawamoto
    Satoshi, Yuki
    Takashi, Meguro
    Kazuteru, Hatanaka
    Minoru, Uebayashi
    Ichiro, Iwanaga
    Michio, Nakamura
    Kazunori, Eto
    Hiroyuki, Okuda
    Masakazu, Abe
    Ayane, Oba
    Nobuhiko, Abe
    Atsushi, Sato
    Hiroshi, Nakatsumi
    Kazuaki, Harada
    Tetsuhito, Muranaka
    Masataka, Yagisawa
    Koji, Oba
    Yuh, Sakata
    Yoshito, Komatsu
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Kawamoto, Y.
    Yuki, S.
    Meguro, T.
    Hatanaka, K.
    Uebayashi, M.
    Iwanaga, I.
    Nakamura, M.
    Eto, K.
    Okuda, H.
    Abe, M.
    Aonuma, A.
    Abe, N.
    Sato, A.
    Nakatsumi, H.
    Muranaka, T.
    Yagisawa, M.
    Oba, K.
    Sakata, Y.
    Sakamoto, N.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum
    Chang, HM
    Kim, TW
    Ryu, BY
    Choi, SJ
    Park, YH
    Lee, JS
    Kim, WK
    Kang, YK
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (05) : 251 - 255
  • [24] A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Enzinger, PC
    Kulke, MH
    Clark, JW
    Ryan, DP
    Kim, H
    Earle, CC
    Vincitore, MM
    Michelini, AL
    Mayer, RJ
    Fuchs, CS
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (12) : 2218 - 2223
  • [25] A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma
    Peter C. Enzinger
    Matthew H. Kulke
    Jeffrey W. Clark
    David P. Ryan
    Haesook Kim
    Craig C. Earle
    Michele M. Vincitore
    Ann L. Michelini
    Robert J. Mayer
    Charles S. Fuchs
    Digestive Diseases and Sciences, 2005, 50 : 2218 - 2223
  • [26] Phase II study of biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer.
    Baek, JH
    Kim, JG
    Sohn, SK
    Song, HS
    Kwon, KY
    Do, YR
    Ryu, HM
    Bae, SH
    Park, GW
    Lee, KH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 325S - 325S
  • [27] A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer
    Kondo, Rie
    Watanabe, Satoshi
    Shoji, Satoshi
    Ichikawa, Kosuke
    Abe, Tetsuya
    Baba, Junko
    Tanaka, Junta
    Tsukada, Hiroki
    Terada, Masaki
    Sato, Kazuhiro
    Maruyama, Yoshie
    Makino, Masato
    Hirata, Akira
    Tanaka, Hiroshi
    Koya, Toshiyuki
    Yoshizawa, Hirohisa
    Kikuchi, Toshiaki
    ONCOLOGY, 2018, 94 (04) : 223 - 232
  • [28] Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas - a multicenter phase II trial (GBFiri).
    Feisthammel, J
    Schoppmeyer, K
    Wiedmann, M
    Zinke, J
    Mossner, J
    Schulze, M
    Caca, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 352S - 352S
  • [29] Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
    Satake, Hironaga
    Sagawa, Tamotsu
    Fujikawa, Koshi
    Hatachi, Yukimasa
    Yasui, Hisateru
    Kotaka, Masahito
    Kato, Takeshi
    Tsuji, Akihito
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (05) : 839 - 845
  • [30] Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
    Hironaga Satake
    Tamotsu Sagawa
    Koshi Fujikawa
    Yukimasa Hatachi
    Hisateru Yasui
    Masahito Kotaka
    Takeshi Kato
    Akihito Tsuji
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 839 - 845
12345